Skip to content
DataLookout
Menu

NCT04420975

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 11 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 54 words Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Jan 31, 2027 to Nov 12, 2026
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
  2. Notable Primary completion date: Jan 31, 2026 to Jan 31, 2027
    • Study completion date: Jan 31, 2027 to Jan 31, 2028
    v11
  3. Notable Primary completion date: Jan 31, 2025 to Jan 31, 2026
    • Study completion date: Jan 31, 2026 to Jan 31, 2027
    • Start date: Oct 29, 2020 to Oct 14, 2020
    v10
  4. Notable Primary completion date: Jan 31, 2024 to Jan 31, 2025
    • Study completion date: Jan 31, 2025 to Jan 31, 2026
    v9
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 14
    • Site details revised
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Notable Eligibility criteria expanded, about 35 wordsv6 Show 8 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 25 to 20
    • Start date: Oct 14, 2020 to Oct 29, 2020
    • Interventions: Definitive Surgical Resection (Procedure), Immunotherapeutic Agent (Drug), Nivolumab (Biological), Radiation Therapy (Radiation) to Definitive Surgical Resection (Procedure), Nanoplexed Poly I:C BO-112 (Biological), Nivolumab (Biological), Radiation Therapy (Radiation)
    • Secondary endpoints revised (2)
    • Study description expanded, about 13 words
    • Site contact updated
    • Collaborators reordered
  2. Minor Collaborators expanded, about 6 wordsv5
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2020 to Oct 14, 2020
    • Site details revised
    v4
  4. Notable Start date: Jun 30, 2020 to Sep 1, 2020
    • Collaborators shortened, about 4 words
    v3
  5. Minor Secondary endpoints: details revised at 2 of 2 entriesv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse events (AEs)
Timeframe: study enrollment through 100 days after the last dose of study drug

Secondary (2)

Immune-oncologic impact of the BO-112 or the combined regimen of nivolumab and BO-112
Pathologic treatment effect

Arms and interventions

Treatment (BO-112, nivolumab)Experimental

Patients receive BO-112 intratumorally on days 8 and 15 or 1, 8, and 15 and nivolumab IV over 30-60 minutes on day 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy on days 8-12 for a total of 5 fractions. Patients then undergo standard of care definitive surgical resection on day 26 to 50.

Procedures: Definitive Surgical Resection

Biologicals: Nanoplexed Poly I:C BO-112, Nivolumab

Radiation: Radiation Therapy

Sites

1 site in 1 country

  • UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, California, United States